PepGen Inc. Common Stock (PEPG) Stock
NASDAQ · PEPG
Key stats
- Market cap
- $364.31M
- Price / Earnings ratio
- -4.4x
- EPS (TTM)
- -$0.78
- Volume
- Loading
- 52-week high
- $7.80
- 52-week low
- $1.31
Source: third-party data provider, as of November 13, 2026
Compare with PEPG
Recent news

Business Wire
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
PEPGAugust 6, 2026
Business Wire
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
PEPG

Business Wire
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
PEPGAugust 6, 2026
Business Wire
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
PEPG

Business Wire
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
PEPGMay 21, 2026
Business Wire
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
PEPG

Zacks Investment Research
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PEPGMay 20, 2026
Zacks Investment Research
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PEPG
Technical indicators
- RSI 14
- 83.62
- MACD 12/26/9
- 0.31
- EMA 9 of MACD
- 0.05
- MACD histogram
- 0.26
- SMA 50
- $2.74
- Price above SMA 50
- EMA 50
- $2.73
- Price above EMA 50
- SMA 200
- $2.94
- Price above SMA 200
- EMA 200
- $3.31
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Strong Sell0
Sell0
Hold0
Buy2
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
261M172M86M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-89.7M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Business Wire
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
PEPGAugust 6, 2026
Business Wire
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
PEPG

Business Wire
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
PEPGAugust 6, 2026
Business Wire
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
PEPG

Business Wire
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
PEPGMay 21, 2026
Business Wire
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
PEPG

Zacks Investment Research
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PEPGMay 20, 2026
Zacks Investment Research
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PEPG

Zacks Investment Research
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know
PEPGMay 13, 2026
Zacks Investment Research
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know
PEPG

Business Wire
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
PEPGMay 12, 2026
Business Wire
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
PEPG

Business Wire
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
PEPGMarch 30, 2026
Business Wire
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
PEPG

Reuters
US FDA puts partial clinical hold on PepGen's muscle disease drug trial
PEPGMarch 4, 2026
Reuters
US FDA puts partial clinical hold on PepGen's muscle disease drug trial
PEPG

Business Wire
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
PEPGMarch 4, 2026
Business Wire
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
PEPG

Business Wire
PepGen Announces Regulatory Updates on FREEDOM2
PEPGMarch 4, 2026
Business Wire
PepGen Announces Regulatory Updates on FREEDOM2
PEPG
About PepGen Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees57
CEODr. James G. McArthur Ph.D.
IPO DateMay 6, 2022
HeadquartersBoston, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. James G. McArthur Ph.D. | President, CEO, Treasurer, Secretary & Director | 1962 |
| Mr. Noel P. Donnelly M.B.A. | Chief Financial Officer | 1970 |
| Mr. Joseph D. Vittiglio Esq., J.D. | Chief Business & Legal Officer and Secretary | 1972 |
| Dr. Kasra Kasraian Ph.D. | Chief Technical Officer | 1967 |
| Ms. Emiko Bryant | Senior Vice President of HR & Administration | — |
| Dr. Hayley Parker Ph.D. | Senior Vice President of Global Regulatory Affairs & Quality | — |
| Dr. Paul D. Streck M.B.A., M.D. | Executive VP and Head of Research & Development | 1964 |
| Ms. Pallavi Lonkar Ph.D. | Vice President & Head of Preclinical | — |
| Ms. Melissa Michaels | Executive Director & Head of Regulatory Affairs CMC | — |
| Mr. Michael Zhao | Vice President & Head of Biometrics | — |
Fundamentals
Valuation
Price-to-book value3.10
Profitability
Return on Equity-51.00%
Return on Assets-44.00%
EBITDA$-70.61M
Trading
Average volume5,881,054
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 83.62
- MACD 12/26/9
- 0.31
- EMA 9 of MACD
- 0.05
- MACD histogram
- 0.26
- SMA 50
- $2.74
- Price above SMA 50
- EMA 50
- $2.73
- Price above EMA 50
- SMA 200
- $2.94
- Price above SMA 200
- EMA 200
- $3.31
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $10.00
- Average
- $15.00
- High
- $20.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | -13.2 | -9.1 | +9.7 | -10.7 | -6.9 | +31.9 | +15.5 | -4.5 | ||||
| 2023 | +17.2 | -2.7 | -19.8 | +20.0 | +5.0 | -39.4 | -34.1 | +6.1 | -21.4 | +10.3 | -3.9 | +26.6 |
| 2024 | +41.5 | +36.8 | -11.6 | -15.2 | +17.5 | -4.8 | -36.2 | -4.4 | -6.5 | -25.5 | -22.1 | -36.5 |
| 2025 | -65.8 | +152.0 | -49.8 | +19.8 | -0.7 | -22.9 | +25.7 | -12.1 | +285.0 | -1.1 | +42.2 | +12.4 |
| 2026 | -28.5 | +22.4 | -72.9 | -5.7 | -14.3 | +22.4 | -2.8 | +59.0 | -22.4 | +6.8 | +96.2 |
Compare stocks
Market cap
$364.31M
-
-
-
Price / Earnings ratio
-4.40
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
5,881,054
-
-
-
Earnings per share
$-0.78
-
-
-



